1. EachPod
EachPod
CCO Oncology Podcast - Podcast

CCO Oncology Podcast

Updates on new data and best practices in the care of patients with cancer across a wide variety of solid tumors and hematologic malignancies from Clinical Care Options. Gain practical clinical insights and strategies and earn CME/CE credit for selected episodes.

Courses Medicine Science Education Health & Fitness Life Sciences
Update frequency
every 9 days
Average duration
23 minutes
Episodes
208
Years Active
2020 - 2025
Share to:
Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer

Expert Insights and FAQs on CDK4/6 Inhibitors in the Care of Today’s Patients With HR-Positive/HER2-Negative Breast Cancer

In this episode, Jame Abraham, MD, FACP; William J. Gradishar, MD, FACP, FASCO; and Laura Spring, MD, review key insights and frequently asked questions related to the CDK4/6 inhibitors used to treat…

00:45:08  |   Thu 20 Feb 2025
Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

Bispecific Antibody Therapy in Relapsed/Refractory Multiple Myeloma: Key Updates From the Annual Hematology Meeting

In this episode, Shaji K. Kumar, MD, reviews key data on bispecific antibodies used to treat patients with relapsed/refractory multiple myeloma recently presented at the 2024 annual American Society …

00:20:01  |   Mon 10 Feb 2025
Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

Clinical Highlights: Oral SERDs for Patients With HR+/HER2- ESR1-Mutated Advanced Breast Cancer

In this episode, listen to Virginia Kaklamani, MD, DSc; Erica L. Mayer, MD, MPH; and Laura M. Spring, MD, share their clinical insights and takeaways from a live symposium, including from key abstrac…

00:36:04  |   Thu 09 Jan 2025
Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

Relapsed/Refractory Multiple Myeloma: Role and Safety of Bispecific Antibodies

In this episode, Caitlin Costello, MD, discusses important topics related to relapsed/refractory (R/R) multiple myeloma (MM), including:

  • 3 bispecific antibodies approved for the treatment of R/R MM th…
00:20:40  |   Tue 22 Oct 2024
Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations

Gastroenteropancreatic Neuroendocrine Tumors: Diagnosis, Findings, and Recommendations

In this episode, Thor R. Halfdanarson, MD, and Jonathan Strosberg, MD, discuss important topics related to gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including:

  • The diagnosis and typical…
00:28:28  |   Wed 16 Oct 2024
ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

ESMO 2024 Congress Highlights in Gynecologic Cancer: New Data Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

In this episode, listen to Ana Oaknin, MD, PhD and Alexandra Leary, MD, PhD, share their clinical insights and takeaways on key updates and new data presented for ovarian, endometrial, and cervical c…

00:30:45  |   Tue 01 Oct 2024
A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

A Cancer Conversation: Optimizing the Care of Patients With CLL Through a Deeper Understanding of BTK Inhibitor Resistance

In this episode, listen to Matthew S. Davids, MD, MMSc​, and Lindsey Roeker, MD, discuss BTK inhibitor resistance and how it shapes treatment choices for patients with CLL, including:

  • Contemporary tre…
00:32:48  |   Mon 30 Sep 2024
Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

Available and Emerging Therapies for Progressive/Recurrent ROS1-Altered Advanced NSCLC

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available and emerging clinical data for second-line and beyond treatments in patients with recu…

00:13:53  |   Fri 06 Sep 2024
Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

Available Clinical Data and Approved First-line Treatments for ROS1-Altered Advanced NSCLC

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the available clinical data in support of frontline treatments for ROS1-altered NSCLC including:

  • Effi…
00:13:46  |   Thu 05 Sep 2024
ROS1-Alterations and Molecular Testing in Advanced NSCLC

ROS1-Alterations and Molecular Testing in Advanced NSCLC

In this episode, listen to Alice T. Shaw, MD, PhD, and Jessica J. Lin, MD, share their thoughts on the current understanding of ROS1 rearrangements in non-small-cell lung cancer tumor biology and its…

00:16:28  |   Wed 28 Aug 2024
Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

Midyear Highlights of Key Data From 2024 Gynecologic Cancer Conferences Informing Treatment of Ovarian, Endometrial, and Cervical Cancers

In this episode, listen to Floor J. Backes, MD, and Angeles Alvarez Secord, MD, MHSc, share their clinical insights and takeaways on new data presented for endometrial, ovarian, and cervical cancers …

00:49:32  |   Mon 05 Aug 2024
Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

Next-Generation Therapeutics for HR+/HER2- Breast Cancer: Spotlight on SERDs

In this episode, Dr Virginia Kaklamani moderates a discussion with Dr Aditya Bardia and Dr Sarah Sammons answering audience questions on the latest data on the use of oral SERDs therapy, including ho…

00:34:45  |   Mon 22 Jul 2024
Current Clinical Practice and NCCN Guidelines for CLL/SLL

Current Clinical Practice and NCCN Guidelines for CLL/SLL

In this podcast episode, Farrukh Awan, MD, Jeremy S. Abramson, MD, MMSc, and Shuo Ma, MD, PhD, discuss real-world patient cases and how to align current clinical practice with the NCCN guidelines for…

00:31:33  |   Thu 18 Jul 2024
Congress to Clinic: Expert Takeaways on Emerging Data for MPNs

Congress to Clinic: Expert Takeaways on Emerging Data for MPNs

In this episode, listen to Dr Brady L. Stein share his clinical insights and takeaways on new data for myeloproliferative neoplasms (MPNs) presented at the 2024 ASCO Annual Meeting and the EHA 2024 C…

00:28:35  |   Fri 12 Jul 2024
CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

CELMoDs: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

In this podcast episode, Julio C. Chavez, MD, MS, and Alan Skarbnik, MD, discuss the emerging role of CELMoDs in NHL care, including:

  • Rationale for targeting CELMoDs in NHL
  • Mechanism of action of CELMo…
00:24:23  |   Thu 11 Jul 2024
Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

Experts Discuss the Role of CDK4/6 Inhibitors in HR+/HER2- Breast Cancer

In this episode, Dr Joyce O’Shaughnessy moderates a discussion with Dr Sara Hurvitz and Dr Erica Mayer answering audience questions on the latest data on incorporating CDK4/6 inhibitors into treatmen…

00:24:30  |   Tue 09 Jul 2024
Congress to Clinic: Expert Takeaways on Emerging Data for AML

Congress to Clinic: Expert Takeaways on Emerging Data for AML

In this episode, listen to Professor Eunice S. Wang, MD, share her clinical insights and takeaways on new data for acute myeloid leukemia (AML) presented at the 2024 ASCO annual meeting and the EHA 2…

00:25:21  |   Mon 08 Jul 2024
Congress to Clinic: Expert Takeaways on Emerging Data for MDS

Congress to Clinic: Expert Takeaways on Emerging Data for MDS

In this episode, listen to Professor Courtney DiNardo, MD, MSCE, share her clinical highlights and clinical takeaways on new data for myelodysplastic syndromes (MDS) presented at the 2024 ASCO annual…

00:19:19  |   Fri 05 Jul 2024
Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

Experiences With Oral SERDs for HR+/HER2- Metastatic Breast Cancer

In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of …

00:25:55  |   Tue 14 May 2024
Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Applying the Latest Evidence and NCCN Guideline Recommendations in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

In this episode, Danielle M. Brander, MD; Deborah Stephens, DO; and Brian Hill, MD, PhD, discuss key aspects of the NCCN CLL guidelines and share strategies for applying these recommendations in your…

00:47:23  |   Tue 07 May 2024
Disclaimer: The podcast and artwork embedded on this page are the property of Clinical Care Options, LLC. This content is not affiliated with or endorsed by eachpod.com.